Will definitely take place at sometime.....it didn't have badly effect on VAL,(quite the opposite...),the most important factor is what are we going to have in the pipe line....no quick fix here IMHO.,folks with no time on their hand will have to look elsewhere....hope to be proven wrong...GLA.
Morning Mate, If they below 0.25 I'll Buy more here and will wait. However, if they consolidate I believe will be better for us. I think Tim, have in mind to consolidate our shares by the end of the year, but 125 x 1 (like VAL did) will not be good for us. Waiting time Mate. Obelix
about hybridan we have seen many time talk about valuation but not to the point,, wait and see cta in Q4,, valuation is back to 2008 today this is the fact ,, for longterm shareholders here have seen many placement ,, from 0.85 to 0.25 ;;,
If all goes to plan, by the end of 2016 Sareum’s pipeline will have a very different shape, moving from one that is purely preclinical to having two candidates in the clinic thereby progressing up the value chain. With the pharmaceutical majors keen to replenish their commercial drug catalogues recent licensing deals have been struck at considerable values.
We might expect a post Phase 1 CHK1 to be out licensed for a total in the low to mid hundred million dollars with 5-10% upfront. Even a 27.5% share of such a deal would represent value well in excess of the current £6.7m market capitalisation and give Sareum the firepower to accelerate the rest of its pipeline or develop new candidates, which could for example be generated from the SKIL® platform (Sareum Kinase Inhibitor Library) which has thus far spawned 3 programmes.
Our sum of the parts valuation of 1.21p suggests that the shares offer good value at present. However we caveat that the possibility that CHK1 is not approved for clinical trials is in our view the biggest short term risk to shareholder value. However whilst this would be this would be disappointing, there remains potential significant value in Sareum’s other two programmes. Conversely a successful CTA would generate scope for upside from our current valuation model.
The drug discovery company last week announced a fund raising of 1.44m at 0.25p. This comes ahead of a pivotal period for the Cambridge based developer of therapies whose science is based on kinase inhibition, as it progresses its candidates towards the clinic. This comes just a few weeks after the early conclusion of Sareum’s Equity Swap Agreement with YA Global Master SPV (YAGM). The earlier facility agreed with YAGM in 2012 expires in September this year and we understand it is not management’s intention to draw down upon it beforehand.
We expect newsflow on all three programs in H2 this year, and to be updated with the results of ongoing pre-clinical work on SAR’s lead candidate Checkpoint Kinase 1 (CHK1) - targeting lung, pancreatic and other cancers. The conclusion of toxicology studies and production of clinical grade drug batches are the last steps ahead of the submission of the Clinical Trial Application (CTA) anticipated to be filed in Q4 which if successful should allow for Phase 1 trials to begin in Q1 2016. We understand that Sareum’s earlier contribution to the collaboration with the Cancer Research Technology Pioneer Fund is sufficient to fund its commitment up to and including the CTA. CTA approval will trigger a required payment of circa £800k which should be sufficient to fund Sareum’s 27.5% share of the costs associated with a Phase 1 trial.
Shortly behind CHK 1 is Aurora+FLT3 Kinases targeting leukaemia & lymphoma with preclinical studies and clinical studies in China funded by Hebei Medical University Biomedical Engineering Center. We expect further preclinical data and a US patent grant this year. Sareum is targeting a CTA for mid-2016 and to commence a clinical trial by the end of 2016. Meanwhile preclinical work continues on TYK2 Kinase Targeting autoimmune diseases in collaboration with SRI international. This funding round will assist the company to nominate a development candidate before the end of this year. Recently the TYK2 program has been expanded to target T-ALL, a type of leukaemia that predominantly affects children.
JHMBNEW. SAR were not involved in this trial. If CHK1 progresses more, this might be the sort of thing it is trailed with in combination in the future. It does have the potential to complement many of the existing and new therapies but first things first - it needs phase 1 to go ahead before anyone risks using it with anything else.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.